Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer.
Colorectal cancer
Gut microbiome
Immune response
Postbiotics
Probiotics
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
accepted:
12
08
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
Colorectal cancer (CRC), the third most common cancer worldwide, develops mainly due to the accumulation of genetic and epigenetic changes over many years. Substantial evidence suggests that gut microbiota plays a significant role in the initiation, progression, and control of CRC, depending on the balance between beneficial and pathogenic microorganisms. Nonetheless, gut microbiota composition by regulating the host immune response may either promote or inhibit CRC. Thus, modification of gut microbiota potentially impacts clinical outcomes of immunotherapy. Previous studies have indicated that therapeutic strategies such as probiotics, prebiotics, and postbiotics enhance the intestinal immune system and improve the efficacy of immunotherapeutic agents, potentially serving as a complementary strategy in cancer immunotherapy. This review discusses the role of the gut microbiota in the onset and development of CRC in relation to the immune response. Additionally, we focus on the effect of strategies manipulating gut microbiome on the immune response and efficacy of immunotherapy against CRC. We demonstrate that manipulation of gut microbiome can enhance immune response and outcomes of immunotherapy through downregulating Treg cells and other immunosuppressive cells while improving the function of T cells within the tumor; however, further research, especially clinical trials, are needed to evaluate its efficacy in cancer treatment.
Identifiants
pubmed: 39162936
doi: 10.1007/s12032-024-02480-9
pii: 10.1007/s12032-024-02480-9
doi:
Substances chimiques
Prebiotics
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
231Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.
pubmed: 30350310
doi: 10.1002/ijc.31937
Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174.
pubmed: 34243011
pmcid: 8273208
doi: 10.1016/j.tranon.2021.101174
De Almeida CV, de Camargo MR, Russo E, Amedei A. Role of diet and gut microbiota on colorectal cancer immunomodulation. World J Gastroenterol. 2019;25(2):151.
pubmed: 30670906
pmcid: 6337022
doi: 10.3748/wjg.v25.i2.151
Hofseth LJ, Hebert JR, Chanda A, Chen H, Love BL, Pena MM, et al. Early-onset colorectal cancer: initial clues and current views. Nat Rev Gastroenterol Hepatol. 2020;17(6):352–64.
pubmed: 32086499
pmcid: 10711686
doi: 10.1038/s41575-019-0253-4
Macrae FA. Colorectal cancer: Epidemiology, risk factors, and protective factors. Uptodate com [ažurirano 9 lipnja 2017. 2016.
Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, Tarkowska A, et al. A new genomic blueprint of the human gut microbiota. Nature. 2019;568(7753):499–504.
pubmed: 30745586
pmcid: 6784870
doi: 10.1038/s41586-019-0965-1
Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem. 2009;20(10):743–52.
pubmed: 19716282
pmcid: 2743755
doi: 10.1016/j.jnutbio.2009.06.001
Malard F, Dore J, Gaugler B, Mohty M. Introduction to host microbiome symbiosis in health and disease. Mucosal Immunol. 2021;14(3):547–54.
pubmed: 33299088
doi: 10.1038/s41385-020-00365-4
Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014;16(7):1024–33.
pubmed: 24798552
pmcid: 4143175
doi: 10.1111/cmi.12308
Alizadehmohajer N, Shojaeifar S, Nedaeinia R, Esparvarinha M, Mohammadi F, Ferns GA, et al. Association between the microbiota and women’s cancers–Cause or consequences? Biomed Pharmacother. 2020;127:110203.
pubmed: 32559847
doi: 10.1016/j.biopha.2020.110203
Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nature Rev Gastroenterol Hepatol. 2019;16(11):690–704. https://doi.org/10.1038/s41575-019-0209-8 .
doi: 10.1038/s41575-019-0209-8
Mizutani S, Yamada T, Yachida S. Significance of the gut microbiome in multistep colorectal carcinogenesis. Cancer Sci. 2020;111(3):766–73.
pubmed: 31910311
pmcid: 7060472
doi: 10.1111/cas.14298
Torres-Maravilla E, Boucard A-S, Mohseni AH, Taghinezhad-S S, Cortes-Perez NG, Bermúdez-Humarán LG. Role of gut microbiota and probiotics in colorectal cancer: onset and progression. Microorganisms. 2021;9(5):1021.
pubmed: 34068653
pmcid: 8151957
doi: 10.3390/microorganisms9051021
Cani PD, Plovier H, Van Hul M, Geurts L, Delzenne NM, Druart C, et al. Endocannabinoids—at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol. 2016;12(3):133–43.
pubmed: 26678807
doi: 10.1038/nrendo.2015.211
Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6(2):320–9.
pubmed: 21850056
doi: 10.1038/ismej.2011.109
Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between Fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS ONE. 2015;10(3):e0119462.
pubmed: 25751261
pmcid: 4353626
doi: 10.1371/journal.pone.0119462
Hashemi Goradel N, Heidarzadeh S, Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N, et al. Fusobacterium nucleatum and colorectal cancer: a mechanistic overview. J Cell Physiol. 2019;234(3):2337–44.
pubmed: 30191984
doi: 10.1002/jcp.27250
Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–15.
pubmed: 23954159
pmcid: 3772512
doi: 10.1016/j.chom.2013.07.007
Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–55.
pubmed: 25680274
pmcid: 4361732
doi: 10.1016/j.immuni.2015.01.010
Deng Z, Mu J, Tseng M, Wattenberg B, Zhuang X, Egilmez NK, et al. Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis. Nat Commun. 2015;6(1):6956.
pubmed: 25907800
doi: 10.1038/ncomms7956
Chung L, Thiele Orberg E, Geis AL, Chan JL, Fu K, DeStefano Shields CE, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. 2018;23(2):203-14.e5. https://doi.org/10.1016/j.chom.2018.01.007 .
doi: 10.1016/j.chom.2018.01.007
pubmed: 29398651
pmcid: 5954996
Li R, Zhou R, Wang H, Li W, Pan M, Yao X, et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. 2019;26(11):2447–63.
pubmed: 30850734
pmcid: 6889446
doi: 10.1038/s41418-019-0312-y
Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Cascio AL, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. 2021;39(5):708-24. e11.
pubmed: 33798472
doi: 10.1016/j.ccell.2021.03.004
Nougayrède J-P, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006;313(5788):848–51.
pubmed: 16902142
doi: 10.1126/science.1127059
Deng Q, Wang C, Yu K, Wang Y, Yang Q, Zhang J, et al. Streptococcus bovis contributes to the development of colorectal cancer via recruiting CD11b+ TLR-4+ cells. Med Sci Monit: Int Med J Exp Clin Res. 2020;26:e921886–91.
doi: 10.12659/MSM.921886
Kim J, Lee HK. Potential role of the gut microbiome in colorectal cancer progression. Front Immunol. 2022;12:807648.
pubmed: 35069592
pmcid: 8777015
doi: 10.3389/fimmu.2021.807648
Attene-Ramos MS, Wagner ED, Gaskins HR, Plewa MJ. Hydrogen sulfide induces direct radical-associated DNA damage. Mol Cancer Res. 2007;5(5):455–9.
pubmed: 17475672
doi: 10.1158/1541-7786.MCR-06-0439
Marquet P, Duncan SH, Chassard C, Bernalier-Donadille A, Flint HJ. Lactate has the potential to promote hydrogen sulphide formation in the human colon. FEMS Microbiol Lett. 2009;299(2):128–34.
pubmed: 19732152
doi: 10.1111/j.1574-6968.2009.01750.x
Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res. 2016;9(12):895–905.
doi: 10.1158/1940-6207.CAPR-16-0209
Savari S, Vinnakota K, Zhang Y, Sjölander A. Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. World J Gastroenterol: WJG. 2014;20(4):968.
pubmed: 24574769
pmcid: 3921548
doi: 10.3748/wjg.v20.i4.968
Tripathy A, Dash J, Kancharla S, Kolli P, Mahajan D, Senapati S, et al. Probiotics: a promising candidate for management of colorectal cancer. Cancers. 2021;13(13):3178.
pubmed: 34202265
pmcid: 8268640
doi: 10.3390/cancers13133178
Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–80.
pubmed: 26311717
doi: 10.1136/gutjnl-2015-310101
Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33:1381–90.
pubmed: 24599709
doi: 10.1007/s10096-014-2081-3
Chen S, Su T, Zhang Y, Lee A, He J, Ge Q, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7. Gut microbes. 2020;11(3):511–25.
pubmed: 31910722
pmcid: 7524269
doi: 10.1080/19490976.2019.1695494
Lee D-W, Han S-W, Kang J-K, Bae JM, Kim H-P, Won J-K, et al. Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25:3389–95.
pubmed: 30062471
doi: 10.1245/s10434-018-6681-5
Ranjbar M, Salehi R, Haghjooy Javanmard S, Rafiee L, Faraji H, Jafarpor S, et al. The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences? A Syst Rev Cancer Cell Int. 2021;21:1–24.
Rubinstein MR, Baik JE, Lagana SM, Han RP, Raab WJ, Sahoo D, et al. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 2019;20(4):e47638.
pubmed: 30833345
pmcid: 6446206
doi: 10.15252/embr.201847638
Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653–61.
pubmed: 26181352
pmcid: 4537376
doi: 10.1001/jamaoncol.2015.1377
Xue Y, Xiao H, Guo S, Xu B, Liao Y, Wu Y, et al. Indoleamine 2, 3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages. Cell Death Dis. 2018;9(3):355.
pubmed: 29500439
pmcid: 5834448
doi: 10.1038/s41419-018-0389-0
Ye X, Wang R, Bhattacharya R, Boulbes DR, Fan F, Xia L, et al. Fusobacterium nucleatum subspecies animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors. Cancer Prev Res. 2017;10(7):398–409.
doi: 10.1158/1940-6207.CAPR-16-0178
Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(4):859–67. https://doi.org/10.1158/1078-0432.ccr-13-1343 .
doi: 10.1158/1078-0432.ccr-13-1343
Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev. 2019. https://doi.org/10.1128/cmr.00060-18 .
doi: 10.1128/cmr.00060-18
pubmed: 30700431
pmcid: 6431131
Sears CL. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev. 2009;22(2):349–69.
pubmed: 19366918
pmcid: 2668231
doi: 10.1128/CMR.00053-08
Purcell RV, Pearson J, Aitchison A, Dixon L, Frizelle FA, Keenan JI. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PLoS ONE. 2017;12(2):e0171602. https://doi.org/10.1371/journal.pone.0171602 .
doi: 10.1371/journal.pone.0171602
pubmed: 28151975
pmcid: 5289627
Toprak NU, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis. 2006;12(8):782–6. https://doi.org/10.1111/j.1469-0691.2006.01494.x .
doi: 10.1111/j.1469-0691.2006.01494.x
Sears CL, Geis AL, Housseau F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest. 2014;124(10):4166–72. https://doi.org/10.1172/jci72334 .
doi: 10.1172/jci72334
pubmed: 25105360
pmcid: 4191034
Tsai C-E, Chiu C-T, Rayner CK, Wu K-L, Chiu Y-C, Hu M-L, et al. Associated factors in Streptococcus bovis bacteremia and colorectal cancer. Kaohsiung J Med Sci. 2016;32(4):196–200.
pubmed: 27185602
doi: 10.1016/j.kjms.2016.03.003
Pasquereau-Kotula E, Martins M, Aymeric L, Dramsi S. Significance of Streptococcus gallolyticus subsp. gallolyticus association with colorectal cancer. Front microbiol. 2018;9:614.
pubmed: 29666615
pmcid: 5891635
doi: 10.3389/fmicb.2018.00614
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.
pubmed: 24336217
doi: 10.1038/nature12820
Yazici C, Wolf PG, Kim H, Cross T-WL, Vermillion K, Carroll T, et al. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut. 2017;66(11):1983–94.
pubmed: 28153960
doi: 10.1136/gutjnl-2016-313321
Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE. 2012;7(6):e39743.
pubmed: 22761885
pmcid: 3386193
doi: 10.1371/journal.pone.0039743
Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR. Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res. 2006;4(1):9–14.
pubmed: 16446402
doi: 10.1158/1541-7786.MCR-05-0126
Pal VK, Bandyopadhyay P, Singh A. Hydrogen sulfide in physiology and pathogenesis of bacteria and viruses. IUBMB Life. 2018;70(5):393–410.
pubmed: 29601123
pmcid: 6029659
doi: 10.1002/iub.1740
Jacouton E, Chain F, Sokol H, Langella P, Bermudez-Humaran LG. Probiotic strain Lactobacillus casei BL23 prevents colitis-associated colorectal cancer. Front Immunol. 2017;8:1553.
pubmed: 29209314
pmcid: 5702231
doi: 10.3389/fimmu.2017.01553
Tiptiri-Kourpeti A, Spyridopoulou K, Santarmaki V, Aindelis G, Tompoulidou E, Lamprianidou EE, et al. Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. PLoS ONE. 2016;11(2):e0147960.
pubmed: 26849051
pmcid: 4744000
doi: 10.1371/journal.pone.0147960
Aindelis G, Tiptiri-Kourpeti A, Lampri E, Spyridopoulou K, Lamprianidou E, Kotsianidis I, et al. Immune responses raised in an experimental colon carcinoma model following oral administration of Lactobacillus casei. Cancers. 2020;12(2):368.
pubmed: 32033490
pmcid: 7072577
doi: 10.3390/cancers12020368
Casas-Solís J, Huizar-López MdR, Irecta-Nájera CA, Pita-López ML, Santerre A. Immunomodulatory effect of Lactobacillus casei in a murine model of colon carcinogenesis. Probiotics Antimicrob Proteins. 2020;12(3):1012–24.
pubmed: 31797281
doi: 10.1007/s12602-019-09611-z
Wang T, Zhang L, Wang P, Liu Y, Wang G, Shan Y, et al. Lactobacillus coryniformis MXJ32 administration ameliorates azoxymethane/dextran sulfate sodium-induced colitis-associated colorectal cancer via reshaping intestinal microenvironment and alleviating inflammatory response. Eur J Nutr. 2022;61(1):85–99.
pubmed: 34185157
doi: 10.1007/s00394-021-02627-8
Zhuo Q, Yu B, Zhou J, Zhang J, Zhang R, Xie J, et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci Rep. 2019;9(1):20128.
pubmed: 31882868
pmcid: 6934597
doi: 10.1038/s41598-019-56661-y
Chen L, Zou Y, Peng J, Lu F, Yin Y, Li F, et al. Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23/Th17 axis. J Immunol Res. 2015;2015:909514.
pubmed: 25973440
pmcid: 4417982
doi: 10.1155/2015/909514
Urbanska AM, Bhathena J, Cherif S, Prakash S. Orally delivered microencapsulated probiotic formulation favorably impacts polyp formation in APC (Min/+) model of intestinal carcinogenesis. Artificial cells, Nanomed Biotechnol. 2016;44(1):1–11.
doi: 10.3109/21691401.2014.898647
Chen C-C, Lin W-C, Kong M-S, Shi HN, Walker WA, Lin C-Y, et al. Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. Br J Nutr. 2012;107(11):1623–34.
pubmed: 21992995
doi: 10.1017/S0007114511004934
Agah S, Alizadeh AM, Mosavi M, Ranji P, Khavari-Daneshvar H, Ghasemian F, et al. More protection of Lactobacillus acidophilus than Bifidobacterium bifidum probiotics on azoxymethane-induced mouse colon cancer. Probiotics and antimicrobial proteins. 2019;11:857–64.
pubmed: 29682678
doi: 10.1007/s12602-018-9425-8
Lee HA, Kim H, Lee K-W, Park K-Y. Dead nano-sized Lactobacillus plantarum inhibits azoxymethane/dextran sulfate sodium-induced colon cancer in Balb/c mice. J Med Food. 2015;18(12):1400–5.
pubmed: 26595186
doi: 10.1089/jmf.2015.3577
Hu J, Wang C, Ye L, Yang W, Huang H, Meng F, et al. Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice. J Biosci. 2015;40:269–79.
pubmed: 25963256
doi: 10.1007/s12038-015-9518-4
Lopez M, Li N, Kataria J, Russell M, Neu J. Live and ultraviolet-inactivated Lactobacillus rhamnosus GG decrease flagellin-induced interleukin-8 production in Caco-2 cells. J Nutr. 2008;138(11):2264–8.
pubmed: 18936229
doi: 10.3945/jn.108.093658
Gamallat Y, Meyiah A, Kuugbee ED, Hago AM, Chiwala G, Awadasseid A, et al. Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. Biomed Pharmacother. 2016;83:536–41.
pubmed: 27447122
doi: 10.1016/j.biopha.2016.07.001
Owens JA, Saeedi BJ, Naudin CR, Hunter-Chang S, Barbian ME, Eboka RU, et al. Lactobacillus rhamnosus GG orchestrates an antitumor immune response. Cell Mol Gastroenterol Hepatol. 2021;12(4):1311–27.
pubmed: 34111601
pmcid: 8463873
doi: 10.1016/j.jcmgh.2021.06.001
Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog. 2012;8(5):e1002714.
pubmed: 22693446
pmcid: 3364948
doi: 10.1371/journal.ppat.1002714
Yang X, Cao Q, Ma B, Xia Y, Liu M, Tian J, et al. Probiotic powder ameliorates colorectal cancer by regulating Bifidobacterium animalis, Clostridium cocleatum, and immune cell composition. PLoS ONE. 2023;18(3):e0277155.
pubmed: 36913356
pmcid: 10010516
doi: 10.1371/journal.pone.0277155
Chen Z-F, Ai L-Y, Wang J-L, Ren L-L, Yu Y-N, Xu J, et al. Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. Future Microbiol. 2015;10(9):1433–45.
pubmed: 26346930
doi: 10.2217/fmb.15.66
Zhou M, Yuan W, Yang B, Pei W, Ma J, Feng Q. Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway. Ann Transl Med. 2022;10(8):478.
pubmed: 35571406
pmcid: 9096358
doi: 10.21037/atm-22-1670
Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol: WJG. 2010;16(2):167.
pubmed: 20066735
pmcid: 2806554
doi: 10.3748/wjg.v16.i2.167
Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, Raja Ali RA. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019;19(1):1–8.
doi: 10.1186/s12876-019-1047-4
Hradicka P, Beal J, Kassayova M, Foey A, Demeckova V. A novel lactic acid bacteria mixture: macrophage-targeted prophylactic intervention in colorectal cancer management. Microorganisms. 2020;8(3):387.
pubmed: 32168834
pmcid: 7142725
doi: 10.3390/microorganisms8030387
Sichetti M, De Marco S, Pagiotti R, Traina G, Pietrella D. Anti-inflammatory effect of multistrain probiotic formulation (L. rhamnosus, B. lactis, and B. longum). Nutrition. 2018;53:95–102.
pubmed: 29674267
doi: 10.1016/j.nut.2018.02.005
Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, et al. Lactobacillus rhamnosus GG induces cGAS/STING-dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022;71(3):521–33.
pubmed: 33685966
doi: 10.1136/gutjnl-2020-323426
Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.
pubmed: 29097494
doi: 10.1126/science.aan3706
Ansaldo E, Slayden LC, Ching KL, Koch MA, Wolf NK, Plichta DR, et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science. 2019;364(6446):1179–84.
pubmed: 31221858
pmcid: 6645389
doi: 10.1126/science.aaw7479
Xu H, Luo H, Zhang J, Li K, Lee M-H. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. Gut Microbes. 2023;15(1):2186114.
pubmed: 36941257
pmcid: 10038047
doi: 10.1080/19490976.2023.2186114
Shi Y, Zheng W, Yang K, Harris KG, Ni K, Xue L, et al. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020;217(5):e20192282.
pubmed: 32142585
pmcid: 7201921
doi: 10.1084/jem.20192282
Molska M, Reguła J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients. 2019;11(10):2453.
pubmed: 31615096
pmcid: 6835638
doi: 10.3390/nu11102453
Galdeano CM, Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol. 2006;13(2):219–26.
pubmed: 16467329
pmcid: 1391937
doi: 10.1128/CVI.13.2.219-226.2006
Cortes-Perez NG, de Moreno de LeBlanc A, Gomez-Gutierrez JG, LeBlanc JG, Bermúdez-Humarán LG. Probiotics and trained immunity. Biomolecules. 2021;11(10):1402.
Evrard B, Coudeyras S, Dosgilbert A, Charbonnel N, Alamé J, Tridon A, et al. Dose-dependent immunomodulation of human dendritic cells by the probiotic Lactobacillus rhamnosus Lcr35. PLoS ONE. 2011;6(4):e18735.
pubmed: 21533162
pmcid: 3078917
doi: 10.1371/journal.pone.0018735
Wang L, Yu K, Zhang X, Yu S. Dual functional roles of the MyD88 signaling in colorectal cancer development. Biomed Pharmacother. 2018;107:177–84.
pubmed: 30086464
doi: 10.1016/j.biopha.2018.07.139
Zhu G, Cheng Z, Huang Y, Zheng W, Yang S, Lin C, et al. MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF-κB/AP-1 signaling pathway. Int J Mol Med. 2020;45(1):131–40.
pubmed: 31746347
Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012;12(2):121–32.
pubmed: 22257950
doi: 10.1038/nrc3204
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350(6264):1084–9.
pubmed: 26541606
pmcid: 4873287
doi: 10.1126/science.aac4255
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews M, Karpinets T, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103.
pubmed: 29097493
doi: 10.1126/science.aan4236
Kim SH, Lim YJ. The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment. Intestinal Research. 2022;20(1):31–42.
pubmed: 34015206
doi: 10.5217/ir.2021.00034
Dwivedi M, Kumar P, Laddha NC, Kemp EH. Induction of regulatory T cells: a role for probiotics and prebiotics to suppress autoimmunity. Autoimmun Rev. 2016;15(4):379–92.
pubmed: 26774011
doi: 10.1016/j.autrev.2016.01.002
Xie X, He Y, Li H, Yu D, Na L, Sun T, et al. Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients. Nutrition. 2019;61:132–42.
pubmed: 30711862
doi: 10.1016/j.nut.2018.10.038
Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr. 2008;101(4):541–50.
pubmed: 18590586
doi: 10.1017/S0007114508019880
Le Bastard Q, Chapelet G, Javaudin F, Lepelletier D, Batard E, Montassier E. The effects of inulin on gut microbial composition: a systematic review of evidence from human studies. Eur J Clin Microbiol Infect Dis. 2020;39:403–13.
pubmed: 31707507
doi: 10.1007/s10096-019-03721-w
Wu RY, Määttänen P, Napper S, Scruten E, Li B, Koike Y, et al. Non-digestible oligosaccharides directly regulate host kinome to modulate host inflammatory responses without alterations in the gut microbiota. Microbiome. 2017;5:1–15.
doi: 10.1186/s40168-017-0357-4
Chu H, Tao X, Sun Z, Hao W, Wei X. Galactooligosaccharides protects against DSS-induced murine colitis through regulating intestinal flora and inhibiting NF-κB pathway. Life Sci. 2020;242:117220.
pubmed: 31881230
doi: 10.1016/j.lfs.2019.117220
Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect Immun. 2006;74(12):6920–8.
pubmed: 16982832
pmcid: 1698067
doi: 10.1128/IAI.01030-06
Searle LE, Cooley WA, Jones G, Nunez A, Crudgington B, Weyer U, et al. Purified galactooligosaccharide, derived from a mixture produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium adhesion and invasion in vitro and in vivo. J Med Microbiol. 2010;59(12):1428–39.
pubmed: 20798214
doi: 10.1099/jmm.0.022780-0
Verediano TA, Viana ML, das Graças Vaz Tostes M, de Oliveira DS, de Carvalho Nunes L, Costa NM. Yacón (Smallanthus sonchifolius) prevented inflammation, oxidative stress, and intestinal alterations in an animal model of colorectal carcinogenesis. J Sci Food Agric. 2020;100(15):5442–9.
pubmed: 32567144
doi: 10.1002/jsfa.10595
Ito H, Takemura N, Sonoyama K, Kawagishi H, Topping DL, Conlon MA, et al. Degree of polymerization of inulin-type fructans differentially affects number of lactic acid bacteria, intestinal immune functions, and immunoglobulin A secretion in the rat cecum. J Agric Food Chem. 2011;59(10):5771–8.
pubmed: 21506616
doi: 10.1021/jf200859z
Fransen F, Sahasrabudhe NM, Elderman M, Bosveld M, El Aidy S, Hugenholtz F, et al. β2→ 1-fructans modulate the immune system in vivo in a microbiota-dependent and-independent fashion. Front Immunol. 2017;8:154.
pubmed: 28261212
pmcid: 5311052
doi: 10.3389/fimmu.2017.00154
Khan I, Huang G, Li X-a, Liao W, Leong WK, Xia W, et al. Mushroom polysaccharides and jiaogulan saponins exert cancer preventive effects by shaping the gut microbiota and microenvironment in ApcMin/+ mice. Pharmacol Res. 2019; 148:104448.
Guo M, Li Z, Huang Y, Shi M. Polysaccharides from Nostoc commune Vaucher activate macrophages via NF-κB and AKT/JNK1/2 pathways to suppress colorectal cancer growth in vivo. Food Funct. 2019;10(7):4269–79.
pubmed: 31259992
doi: 10.1039/C9FO00595A
Bennedsen AL, Furbo S, Bjarnsholt T, Raskov H, Gögenur I, Kvich L. The gut microbiota can orchestrate the signaling pathways in colorectal cancer. APMIS. 2022;130(3):121–39.
pubmed: 35007370
doi: 10.1111/apm.13206
Wang Y, Zeng Y, Zhu L, Wan J, Lei N, Yao X, et al. Polysaccharides from Lentinus edodes inhibits lymphangiogenesis via the toll-like receptor 4/JNK pathway of cancer-associated fibroblasts. Front Oncol. 2021;10:547683.
pubmed: 33643892
pmcid: 7907162
doi: 10.3389/fonc.2020.547683
Prajapati N, Patel J, Singh S, Yadav VK, Joshi C, Patani A, et al. Postbiotic production: harnessing the power of microbial metabolites for health applications. Front Microbiol. 2023;14:1306192.
pubmed: 38169918
pmcid: 10758465
doi: 10.3389/fmicb.2023.1306192
Eslami M, Yousefi B, Kokhaei P, Hemati M, Nejad ZR, Arabkari V, et al. Importance of probiotics in the prevention and treatment of colorectal cancer. J Cell Physiol. 2019;234(10):17127–43.
pubmed: 30912128
doi: 10.1002/jcp.28473
Cruz BC, Sarandy MM, Messias AC, Gonçalves RV, Ferreira CL, Peluzio MC. Preclinical and clinical relevance of probiotics and synbiotics in colorectal carcinogenesis: a systematic review. Nutr Rev. 2020;78(8):667–87.
pubmed: 31917829
doi: 10.1093/nutrit/nuz087
Marcon LDN, de Sousa Moraes LF, dos Santos Cruz BC, de Oliveira Teixeira MD, Bruno TCV, Ribeiro IE, et al. Yacon (Smallanthus sonchifolius)-based product increases fecal short-chain fatty acids and enhances regulatory T cells by downregulating RORγt in the colon of BALB/c mice. J Funct Foods. 2019;55:333–42.
doi: 10.1016/j.jff.2019.02.039
Tamanai-Shacoori Z, Smida I, Bousarghin L, Loreal O, Meuric V, Fong SB, et al. Roseburia spp.: a marker of health? Future Microbiol. 2017;12(2):157–70.
pubmed: 28139139
doi: 10.2217/fmb-2016-0130
Uchiyama K, Sakiyama T, Hasebe T, Musch MW, Miyoshi H, Nakagawa Y, et al. Butyrate and bioactive proteolytic form of Wnt-5a regulate colonic epithelial proliferation and spatial development. Sci Rep. 2016;6(1):32094.
pubmed: 27561676
pmcid: 4999796
doi: 10.1038/srep32094
Nastasi C, Candela M, Bonefeld CM, Geisler C, Hansen M, Krejsgaard T, et al. The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep. 2015;5(1):16148.
pubmed: 26541096
pmcid: 4635422
doi: 10.1038/srep16148
Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology. 2000;118(4):724–34.
pubmed: 10734024
doi: 10.1016/S0016-5085(00)70142-9
Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A is a G-protein–coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Can Res. 2009;69(7):2826–32.
doi: 10.1158/0008-5472.CAN-08-4466
Arpaia N, Campbell C, Fan X, Dikiy S, Van Der Veeken J, Deroos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–5.
pubmed: 24226773
pmcid: 3869884
doi: 10.1038/nature12726
Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–73.
pubmed: 23828891
doi: 10.1126/science.1241165
Chen GY. The role of the gut microbiome in colorectal cancer. Clin Colon Rectal Surg. 2018;31(03):192–8.
pubmed: 29720905
pmcid: 5929887
doi: 10.1055/s-0037-1602239
Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci. 2014;111(6):2247–52.
pubmed: 24390544
pmcid: 3926023
doi: 10.1073/pnas.1322269111
Scott NA, Andrusaite A, Andersen P, Lawson M, Alcon-Giner C, Leclaire C, et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci Transl Med. 2018;10(464):eaao4755.
pubmed: 30355800
pmcid: 6548564
doi: 10.1126/scitranslmed.aao4755
Ji J, Shu D, Zheng M, Wang J, Luo C, Wang Y, et al. Microbial metabolite butyrate facilitates M2 macrophage polarization and function. Sci Rep. 2016;6(1):24838.
pubmed: 27094081
pmcid: 4837405
doi: 10.1038/srep24838
Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107–18.
pubmed: 16009137
doi: 10.1016/j.cell.2005.05.007
Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. 2010;330(6012):1768–73.
pubmed: 21205662
pmcid: 3159383
doi: 10.1126/science.1195568
Chan JL, Wu S, Geis AL, Chan GV, Gomes TA, Beck SE, et al. Non-toxigenic Bacteroides fragilis (NTBF) administration reduces bacteria-driven chronic colitis and tumor development independent of polysaccharide A. Mucosal Immunol. 2019;12(1):164–77.
pubmed: 30279518
doi: 10.1038/s41385-018-0085-5
Sugimura N, Li Q, Chu ESH, Lau HCH, Fong W, Liu W, et al. Lactobacillus gallinarum modulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis. Gut. 2022;71(10):2011–21.
doi: 10.1136/gutjnl-2020-323951
Zhang Q, Zhao Q, Li T, Lu L, Wang F, Zhang H, et al. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity. Cell Metab. 2023;35(6):943-60.e9.
pubmed: 37192617
doi: 10.1016/j.cmet.2023.04.015
Kang X, Liu C, Ding Y, Ni Y, Ji F, Lau HCH, et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells. Gut. 2023;72(11):2112–22.
pubmed: 37491158
doi: 10.1136/gutjnl-2023-330291
Fong W, Li Q, Ji F, Liang W, Lau HCH, Kang X, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis. Gut. 2023;72(12):2272–85.
pubmed: 37770127
doi: 10.1136/gutjnl-2023-329543
Kawanabe-Matsuda H, Takeda K, Nakamura M, Makino S, Karasaki T, Kakimi K, et al. Dietary lactobacillus-derived exopolysaccharide enhances immune-checkpoint blockade therapy. Cancer Discov. 2022;12(5):1336–55.
pubmed: 35180303
pmcid: 9662940
doi: 10.1158/2159-8290.CD-21-0929
Gao G, Shen S, Zhang T, Zhang J, Huang S, Sun Z, et al. Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine. 2023. https://doi.org/10.1016/j.ebiom.2023.104533 .
doi: 10.1016/j.ebiom.2023.104533
pubmed: 38251462
pmcid: 10628343
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84.
pubmed: 26541610
pmcid: 4721659
doi: 10.1126/science.aad1329
Kaisar MM, Pelgrom LR, Van der Ham AJ, Yazdanbakhsh M, Everts B. Butyrate conditions human dendritic cells to prime type 1 regulatory T cells via both histone deacetylase inhibition and G protein-coupled receptor 109A signaling. Front Immunol. 2017;8:1429.
pubmed: 29163504
pmcid: 5670331
doi: 10.3389/fimmu.2017.01429
Liu M, Xie W, Wan X, Deng T. Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice. Int Immunopharmacol. 2020;88:106862.
pubmed: 32771947
doi: 10.1016/j.intimp.2020.106862
Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. Cancer Lett. 2020;469:456–67.
pubmed: 31734354
doi: 10.1016/j.canlet.2019.11.019
Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, et al. The gut microbiome is associated with clinical response to anti–PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8(10):1251–61.
pubmed: 32855157
doi: 10.1158/2326-6066.CIR-19-1014
Chen J, Liang H, Lu J, He Y, Lai R. Probiotics improve postoperative adaptive immunity in colorectal cancer patients: a systematic review and meta-analysis. Nutr Cancer. 2022;74(8):2975–82.
pubmed: 35341415
doi: 10.1080/01635581.2022.2056619
McHale D, Francisco-Anderson L, Sandy P, Shariffudin S, Goldberg M, Gardner H, et al. P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity. Ann Oncol. 2020;31:S195.
doi: 10.1016/j.annonc.2020.04.407
Kiousi DE, Kouroutzidou AZ, Neanidis K, Karavanis E, Matthaios D, Pappa A, et al. The role of the gut Microbiome in cancer Immunotherapy: current knowledge and future directions. Cancers. 2023;15(7):2101.
pubmed: 37046762
pmcid: 10093606
doi: 10.3390/cancers15072101
Xie J, Liu M, Deng X, Tang Y, Zheng S, Ou X, et al. Gut microbiota reshapes cancer immunotherapy efficacy: mechanisms and therapeutic strategies. Imeta. 2024;3(1):e156.
pubmed: 38868510
pmcid: 10989143
doi: 10.1002/imt2.156
Khan U, Ho K, Hwang EK, Peña C, Brouwer J, Hoffman K, et al. Impact of use of antibiotics on response to immune checkpoint inhibitors and tumor microenvironment. Am J Clin Oncol. 2021;44(6):247–53.
pubmed: 33826550
doi: 10.1097/COC.0000000000000813
Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, et al. Antibiotic exposure does not impact immune checkpoint blockade response in MSI-H/dMMR metastatic colorectal cancer: a single-center experience. Oncologist. 2022;27(11):952–7.
pubmed: 35946836
pmcid: 9632313
doi: 10.1093/oncolo/oyac162
Gao Y, Bi D, Xie R, Li M, Guo J, Liu H, et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):398.
pubmed: 34795206
pmcid: 8602417
doi: 10.1038/s41392-021-00795-x
Jiang S-S, Xie Y-L, Xiao X-Y, Kang Z-R, Lin X-L, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31(5):781-97.e9.
pubmed: 37130518
doi: 10.1016/j.chom.2023.04.010
Botticelli A, Vernocchi P, Marini F, Quagliariello A, Cerbelli B, Reddel S, et al. Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. J Transl Med. 2020;18:1–10.
doi: 10.1186/s12967-020-02231-0
Nomura M, Nagatomo R, Doi K, Shimizu J, Baba K, Saito T, et al. Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw Open. 2020;3(4):e202895.
pubmed: 32297948
pmcid: 7163404
doi: 10.1001/jamanetworkopen.2020.2895
Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021;53(2):156–65.
pubmed: 33462485
pmcid: 8515199
doi: 10.1038/s41588-020-00763-1
Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021;53(1):33–42.
pubmed: 33159374
doi: 10.1111/apt.16148